nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—AHR—lung cancer	0.292	0.717	CbGaD
Leflunomide—PTK2B—Crizotinib—lung cancer	0.172	0.445	CbGbCtD
Leflunomide—ABCG2—lung cancer	0.115	0.284	CbGaD
Leflunomide—ABCG2—Topotecan—lung cancer	0.029	0.0752	CbGbCtD
Leflunomide—ABCG2—Gefitinib—lung cancer	0.0265	0.0688	CbGbCtD
Leflunomide—ABCG2—Teniposide—lung cancer	0.0257	0.0667	CbGbCtD
Leflunomide—ABCG2—Erlotinib—lung cancer	0.0157	0.0407	CbGbCtD
Leflunomide—ABCG2—Paclitaxel—lung cancer	0.0144	0.0372	CbGbCtD
Leflunomide—ABCG2—Irinotecan—lung cancer	0.0142	0.0367	CbGbCtD
Leflunomide—ABCG2—Cisplatin—lung cancer	0.0116	0.0299	CbGbCtD
Leflunomide—ABCG2—Etoposide—lung cancer	0.0113	0.0294	CbGbCtD
Leflunomide—ABCG2—Docetaxel—lung cancer	0.0104	0.0269	CbGbCtD
Leflunomide—CYP2C9—Gefitinib—lung cancer	0.00986	0.0256	CbGbCtD
Leflunomide—CYP2C9—Teniposide—lung cancer	0.00956	0.0248	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—lung cancer	0.00774	0.0201	CbGbCtD
Leflunomide—ABCG2—Methotrexate—lung cancer	0.0075	0.0194	CbGbCtD
Leflunomide—CYP1A2—Erlotinib—lung cancer	0.00647	0.0168	CbGbCtD
Leflunomide—CYP2C9—Paclitaxel—lung cancer	0.00534	0.0138	CbGbCtD
Leflunomide—CYP1A2—Etoposide—lung cancer	0.00468	0.0121	CbGbCtD
Leflunomide—CYP2C9—Cisplatin—lung cancer	0.00429	0.0111	CbGbCtD
Leflunomide—DHODH—cardiac atrium—lung cancer	0.00144	0.116	CbGeAlD
Leflunomide—PTK2B—respiratory system—lung cancer	0.00131	0.106	CbGeAlD
Leflunomide—DHODH—lung—lung cancer	0.0011	0.0888	CbGeAlD
Leflunomide—AHR—bronchus—lung cancer	0.000887	0.0717	CbGeAlD
Leflunomide—AHR—trachea—lung cancer	0.000796	0.0644	CbGeAlD
Leflunomide—PTK2B—bone marrow—lung cancer	0.000768	0.0621	CbGeAlD
Leflunomide—DHODH—lymph node—lung cancer	0.000751	0.0607	CbGeAlD
Leflunomide—AHR—cardiac atrium—lung cancer	0.000748	0.0605	CbGeAlD
Leflunomide—PTK2B—lung—lung cancer	0.000696	0.0563	CbGeAlD
Leflunomide—AHR—bone marrow—lung cancer	0.000632	0.0511	CbGeAlD
Leflunomide—CYP2C9—mammary gland—lung cancer	0.000573	0.0463	CbGeAlD
Leflunomide—AHR—lung—lung cancer	0.000572	0.0463	CbGeAlD
Leflunomide—PTK2B—lymph node—lung cancer	0.000476	0.0385	CbGeAlD
Leflunomide—CYP1A2—respiratory system—lung cancer	0.000402	0.0325	CbGeAlD
Leflunomide—AHR—lymph node—lung cancer	0.000391	0.0316	CbGeAlD
Leflunomide—ABCG2—bone marrow—lung cancer	0.000245	0.0198	CbGeAlD
Leflunomide—ABCG2—lung—lung cancer	0.000222	0.0179	CbGeAlD
Leflunomide—CYP1A2—lung—lung cancer	0.000214	0.0173	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—lung cancer	0.000207	1	CrCbGaD
Leflunomide—ABCG2—lymph node—lung cancer	0.000152	0.0123	CbGeAlD
Leflunomide—Asthenia—Irinotecan—lung cancer	3.74e-05	0.000315	CcSEcCtD
Leflunomide—Fatigue—Etoposide—lung cancer	3.74e-05	0.000315	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	3.73e-05	0.000314	CcSEcCtD
Leflunomide—Pain—Etoposide—lung cancer	3.71e-05	0.000312	CcSEcCtD
Leflunomide—Constipation—Etoposide—lung cancer	3.71e-05	0.000312	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—lung cancer	3.7e-05	0.000311	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—lung cancer	3.7e-05	0.000311	CcSEcCtD
Leflunomide—Decreased appetite—Paclitaxel—lung cancer	3.69e-05	0.000311	CcSEcCtD
Leflunomide—Dry mouth—Docetaxel—lung cancer	3.67e-05	0.000309	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—lung cancer	3.67e-05	0.000309	CcSEcCtD
Leflunomide—Haemoglobin—Methotrexate—lung cancer	3.67e-05	0.000309	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Paclitaxel—lung cancer	3.67e-05	0.000309	CcSEcCtD
Leflunomide—Fatigue—Paclitaxel—lung cancer	3.66e-05	0.000308	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—lung cancer	3.65e-05	0.000308	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—lung cancer	3.65e-05	0.000308	CcSEcCtD
Leflunomide—Pollakiuria—Doxorubicin—lung cancer	3.65e-05	0.000307	CcSEcCtD
Leflunomide—Asthenia—Gemcitabine—lung cancer	3.64e-05	0.000307	CcSEcCtD
Leflunomide—Constipation—Paclitaxel—lung cancer	3.63e-05	0.000306	CcSEcCtD
Leflunomide—Pain—Paclitaxel—lung cancer	3.63e-05	0.000306	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—lung cancer	3.63e-05	0.000305	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—lung cancer	3.61e-05	0.000304	CcSEcCtD
Leflunomide—Anaphylactic shock—Docetaxel—lung cancer	3.6e-05	0.000303	CcSEcCtD
Leflunomide—Pruritus—Gemcitabine—lung cancer	3.59e-05	0.000302	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—lung cancer	3.58e-05	0.000302	CcSEcCtD
Leflunomide—Infection—Docetaxel—lung cancer	3.58e-05	0.000301	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—lung cancer	3.58e-05	0.000301	CcSEcCtD
Leflunomide—Feeling abnormal—Etoposide—lung cancer	3.57e-05	0.000301	CcSEcCtD
Leflunomide—Hyperglycaemia—Doxorubicin—lung cancer	3.57e-05	0.0003	CcSEcCtD
Leflunomide—Diarrhoea—Irinotecan—lung cancer	3.57e-05	0.0003	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—lung cancer	3.55e-05	0.000298	CcSEcCtD
Leflunomide—Gastrointestinal pain—Etoposide—lung cancer	3.54e-05	0.000298	CcSEcCtD
Leflunomide—Nervous system disorder—Docetaxel—lung cancer	3.53e-05	0.000297	CcSEcCtD
Leflunomide—Thrombocytopenia—Docetaxel—lung cancer	3.53e-05	0.000297	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—lung cancer	3.52e-05	0.000297	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—lung cancer	3.52e-05	0.000297	CcSEcCtD
Leflunomide—Tachycardia—Docetaxel—lung cancer	3.52e-05	0.000296	CcSEcCtD
Leflunomide—Feeling abnormal—Paclitaxel—lung cancer	3.5e-05	0.000295	CcSEcCtD
Leflunomide—Skin disorder—Docetaxel—lung cancer	3.5e-05	0.000295	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—lung cancer	3.49e-05	0.000294	CcSEcCtD
Leflunomide—Hypersensitivity—Cisplatin—lung cancer	3.49e-05	0.000293	CcSEcCtD
Leflunomide—Gastrointestinal pain—Paclitaxel—lung cancer	3.48e-05	0.000293	CcSEcCtD
Leflunomide—Diarrhoea—Gemcitabine—lung cancer	3.47e-05	0.000292	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—lung cancer	3.46e-05	0.000292	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—lung cancer	3.46e-05	0.000291	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—lung cancer	3.46e-05	0.000291	CcSEcCtD
Leflunomide—Dizziness—Irinotecan—lung cancer	3.45e-05	0.00029	CcSEcCtD
Leflunomide—Urticaria—Etoposide—lung cancer	3.44e-05	0.00029	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—lung cancer	3.44e-05	0.000289	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—lung cancer	3.44e-05	0.000289	CcSEcCtD
Leflunomide—Anorexia—Docetaxel—lung cancer	3.43e-05	0.000289	CcSEcCtD
Leflunomide—Abdominal pain—Etoposide—lung cancer	3.43e-05	0.000288	CcSEcCtD
Leflunomide—Body temperature increased—Etoposide—lung cancer	3.43e-05	0.000288	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—lung cancer	3.43e-05	0.000288	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—lung cancer	3.43e-05	0.000288	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—lung cancer	3.42e-05	0.000287	CcSEcCtD
Leflunomide—Asthenia—Cisplatin—lung cancer	3.39e-05	0.000286	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—lung cancer	3.39e-05	0.000285	CcSEcCtD
Leflunomide—Urticaria—Paclitaxel—lung cancer	3.38e-05	0.000284	CcSEcCtD
Leflunomide—Hypotension—Docetaxel—lung cancer	3.37e-05	0.000283	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—lung cancer	3.36e-05	0.000283	CcSEcCtD
Leflunomide—Body temperature increased—Paclitaxel—lung cancer	3.36e-05	0.000283	CcSEcCtD
Leflunomide—Abdominal pain—Paclitaxel—lung cancer	3.36e-05	0.000283	CcSEcCtD
Leflunomide—Hepatobiliary disease—Doxorubicin—lung cancer	3.33e-05	0.000281	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—lung cancer	3.32e-05	0.00028	CcSEcCtD
Leflunomide—Vomiting—Irinotecan—lung cancer	3.31e-05	0.000279	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—lung cancer	3.31e-05	0.000278	CcSEcCtD
Leflunomide—Immune system disorder—Methotrexate—lung cancer	3.3e-05	0.000278	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—lung cancer	3.29e-05	0.000277	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—lung cancer	3.29e-05	0.000277	CcSEcCtD
Leflunomide—Rash—Irinotecan—lung cancer	3.29e-05	0.000277	CcSEcCtD
Leflunomide—Dermatitis—Irinotecan—lung cancer	3.28e-05	0.000276	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Docetaxel—lung cancer	3.28e-05	0.000276	CcSEcCtD
Leflunomide—Chills—Methotrexate—lung cancer	3.28e-05	0.000276	CcSEcCtD
Leflunomide—Headache—Irinotecan—lung cancer	3.26e-05	0.000275	CcSEcCtD
Leflunomide—Insomnia—Docetaxel—lung cancer	3.26e-05	0.000274	CcSEcCtD
Leflunomide—Diarrhoea—Cisplatin—lung cancer	3.24e-05	0.000272	CcSEcCtD
Leflunomide—Paraesthesia—Docetaxel—lung cancer	3.23e-05	0.000272	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—lung cancer	3.23e-05	0.000272	CcSEcCtD
Leflunomide—Vomiting—Gemcitabine—lung cancer	3.23e-05	0.000272	CcSEcCtD
Leflunomide—Dyspnoea—Docetaxel—lung cancer	3.21e-05	0.00027	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—lung cancer	3.2e-05	0.000269	CcSEcCtD
Leflunomide—Rash—Gemcitabine—lung cancer	3.2e-05	0.000269	CcSEcCtD
Leflunomide—Dermatitis—Gemcitabine—lung cancer	3.2e-05	0.000269	CcSEcCtD
Leflunomide—Hypersensitivity—Etoposide—lung cancer	3.19e-05	0.000269	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—lung cancer	3.18e-05	0.000268	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—lung cancer	3.18e-05	0.000268	CcSEcCtD
Leflunomide—Headache—Gemcitabine—lung cancer	3.18e-05	0.000268	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—lung cancer	3.17e-05	0.000267	CcSEcCtD
Leflunomide—Dyspepsia—Docetaxel—lung cancer	3.17e-05	0.000267	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—lung cancer	3.16e-05	0.000266	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—lung cancer	3.16e-05	0.000266	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—lung cancer	3.14e-05	0.000264	CcSEcCtD
Leflunomide—Decreased appetite—Docetaxel—lung cancer	3.13e-05	0.000264	CcSEcCtD
Leflunomide—Hypersensitivity—Paclitaxel—lung cancer	3.13e-05	0.000264	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—lung cancer	3.12e-05	0.000263	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—lung cancer	3.12e-05	0.000262	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—lung cancer	3.12e-05	0.000262	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Docetaxel—lung cancer	3.11e-05	0.000262	CcSEcCtD
Leflunomide—Asthenia—Etoposide—lung cancer	3.11e-05	0.000262	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—lung cancer	3.11e-05	0.000262	CcSEcCtD
Leflunomide—Fatigue—Docetaxel—lung cancer	3.11e-05	0.000261	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—lung cancer	3.1e-05	0.000261	CcSEcCtD
Leflunomide—Nausea—Irinotecan—lung cancer	3.1e-05	0.000261	CcSEcCtD
Leflunomide—Pain—Docetaxel—lung cancer	3.08e-05	0.000259	CcSEcCtD
Leflunomide—Constipation—Docetaxel—lung cancer	3.08e-05	0.000259	CcSEcCtD
Leflunomide—Back pain—Methotrexate—lung cancer	3.08e-05	0.000259	CcSEcCtD
Leflunomide—Pruritus—Etoposide—lung cancer	3.07e-05	0.000258	CcSEcCtD
Leflunomide—Asthenia—Paclitaxel—lung cancer	3.05e-05	0.000257	CcSEcCtD
Leflunomide—Nausea—Gemcitabine—lung cancer	3.01e-05	0.000254	CcSEcCtD
Leflunomide—Vomiting—Cisplatin—lung cancer	3.01e-05	0.000253	CcSEcCtD
Leflunomide—Pruritus—Paclitaxel—lung cancer	3.01e-05	0.000253	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—lung cancer	3e-05	0.000252	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—lung cancer	2.99e-05	0.000252	CcSEcCtD
Leflunomide—Rash—Cisplatin—lung cancer	2.98e-05	0.000251	CcSEcCtD
Leflunomide—Dermatitis—Cisplatin—lung cancer	2.98e-05	0.000251	CcSEcCtD
Leflunomide—Feeling abnormal—Docetaxel—lung cancer	2.97e-05	0.00025	CcSEcCtD
Leflunomide—Diarrhoea—Etoposide—lung cancer	2.97e-05	0.00025	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—lung cancer	2.96e-05	0.000249	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—lung cancer	2.95e-05	0.000248	CcSEcCtD
Leflunomide—Gastrointestinal pain—Docetaxel—lung cancer	2.95e-05	0.000248	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—lung cancer	2.94e-05	0.000247	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—lung cancer	2.94e-05	0.000247	CcSEcCtD
Leflunomide—Diarrhoea—Paclitaxel—lung cancer	2.91e-05	0.000245	CcSEcCtD
Leflunomide—Malaise—Methotrexate—lung cancer	2.87e-05	0.000241	CcSEcCtD
Leflunomide—Dizziness—Etoposide—lung cancer	2.87e-05	0.000241	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—lung cancer	2.86e-05	0.000241	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—lung cancer	2.86e-05	0.000241	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—lung cancer	2.85e-05	0.00024	CcSEcCtD
Leflunomide—Abdominal pain—Docetaxel—lung cancer	2.85e-05	0.00024	CcSEcCtD
Leflunomide—Body temperature increased—Docetaxel—lung cancer	2.85e-05	0.00024	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—lung cancer	2.85e-05	0.00024	CcSEcCtD
Leflunomide—Chills—Doxorubicin—lung cancer	2.84e-05	0.000239	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—lung cancer	2.83e-05	0.000238	CcSEcCtD
Leflunomide—Dizziness—Paclitaxel—lung cancer	2.81e-05	0.000237	CcSEcCtD
Leflunomide—Nausea—Cisplatin—lung cancer	2.81e-05	0.000237	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—lung cancer	2.8e-05	0.000235	CcSEcCtD
Leflunomide—Cough—Methotrexate—lung cancer	2.78e-05	0.000234	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—lung cancer	2.77e-05	0.000233	CcSEcCtD
Leflunomide—Vomiting—Etoposide—lung cancer	2.76e-05	0.000232	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—lung cancer	2.75e-05	0.000232	CcSEcCtD
Leflunomide—Rash—Etoposide—lung cancer	2.73e-05	0.00023	CcSEcCtD
Leflunomide—Dermatitis—Etoposide—lung cancer	2.73e-05	0.00023	CcSEcCtD
Leflunomide—Headache—Etoposide—lung cancer	2.72e-05	0.000229	CcSEcCtD
Leflunomide—Flatulence—Doxorubicin—lung cancer	2.71e-05	0.000228	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—lung cancer	2.71e-05	0.000228	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—lung cancer	2.71e-05	0.000228	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—lung cancer	2.71e-05	0.000228	CcSEcCtD
Leflunomide—Vomiting—Paclitaxel—lung cancer	2.7e-05	0.000227	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—lung cancer	2.7e-05	0.000227	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.69e-05	0.000226	CcSEcCtD
Leflunomide—Rash—Paclitaxel—lung cancer	2.68e-05	0.000226	CcSEcCtD
Leflunomide—Dermatitis—Paclitaxel—lung cancer	2.68e-05	0.000225	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—lung cancer	2.68e-05	0.000225	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—lung cancer	2.66e-05	0.000224	CcSEcCtD
Leflunomide—Headache—Paclitaxel—lung cancer	2.66e-05	0.000224	CcSEcCtD
Leflunomide—Hypersensitivity—Docetaxel—lung cancer	2.65e-05	0.000223	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—lung cancer	2.65e-05	0.000223	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—lung cancer	2.6e-05	0.000219	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—lung cancer	2.6e-05	0.000219	CcSEcCtD
Leflunomide—Asthenia—Docetaxel—lung cancer	2.58e-05	0.000218	CcSEcCtD
Leflunomide—Infection—Methotrexate—lung cancer	2.58e-05	0.000217	CcSEcCtD
Leflunomide—Nausea—Etoposide—lung cancer	2.57e-05	0.000217	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—lung cancer	2.56e-05	0.000215	CcSEcCtD
Leflunomide—Pruritus—Docetaxel—lung cancer	2.55e-05	0.000215	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—lung cancer	2.55e-05	0.000214	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—lung cancer	2.55e-05	0.000214	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—lung cancer	2.54e-05	0.000214	CcSEcCtD
Leflunomide—Nausea—Paclitaxel—lung cancer	2.52e-05	0.000212	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—lung cancer	2.52e-05	0.000212	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—lung cancer	2.51e-05	0.000211	CcSEcCtD
Leflunomide—Malaise—Doxorubicin—lung cancer	2.48e-05	0.000209	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—lung cancer	2.47e-05	0.000208	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—lung cancer	2.47e-05	0.000208	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—lung cancer	2.47e-05	0.000208	CcSEcCtD
Leflunomide—Diarrhoea—Docetaxel—lung cancer	2.46e-05	0.000207	CcSEcCtD
Leflunomide—Palpitations—Doxorubicin—lung cancer	2.43e-05	0.000205	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—lung cancer	2.43e-05	0.000204	CcSEcCtD
Leflunomide—Cough—Doxorubicin—lung cancer	2.4e-05	0.000202	CcSEcCtD
Leflunomide—Dizziness—Docetaxel—lung cancer	2.38e-05	0.0002	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—lung cancer	2.38e-05	0.0002	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—lung cancer	2.37e-05	0.000199	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—lung cancer	2.35e-05	0.000198	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—lung cancer	2.35e-05	0.000197	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—lung cancer	2.35e-05	0.000197	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—lung cancer	2.35e-05	0.000197	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—lung cancer	2.34e-05	0.000197	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—lung cancer	2.33e-05	0.000196	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.33e-05	0.000196	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—lung cancer	2.32e-05	0.000195	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—lung cancer	2.31e-05	0.000195	CcSEcCtD
Leflunomide—Dry mouth—Doxorubicin—lung cancer	2.29e-05	0.000193	CcSEcCtD
Leflunomide—Vomiting—Docetaxel—lung cancer	2.29e-05	0.000193	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—lung cancer	2.29e-05	0.000192	CcSEcCtD
Leflunomide—Rash—Docetaxel—lung cancer	2.27e-05	0.000191	CcSEcCtD
Leflunomide—Dermatitis—Docetaxel—lung cancer	2.27e-05	0.000191	CcSEcCtD
Leflunomide—Decreased appetite—Methotrexate—lung cancer	2.26e-05	0.00019	CcSEcCtD
Leflunomide—Headache—Docetaxel—lung cancer	2.26e-05	0.00019	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—lung cancer	2.25e-05	0.000189	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—lung cancer	2.24e-05	0.000189	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—lung cancer	2.24e-05	0.000188	CcSEcCtD
Leflunomide—Infection—Doxorubicin—lung cancer	2.23e-05	0.000188	CcSEcCtD
Leflunomide—Pain—Methotrexate—lung cancer	2.22e-05	0.000187	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—lung cancer	2.2e-05	0.000186	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—lung cancer	2.2e-05	0.000185	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—lung cancer	2.19e-05	0.000185	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—lung cancer	2.18e-05	0.000184	CcSEcCtD
Leflunomide—Hyperhidrosis—Doxorubicin—lung cancer	2.17e-05	0.000183	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—lung cancer	2.14e-05	0.00018	CcSEcCtD
Leflunomide—Nausea—Docetaxel—lung cancer	2.14e-05	0.00018	CcSEcCtD
Leflunomide—Feeling abnormal—Methotrexate—lung cancer	2.14e-05	0.00018	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—lung cancer	2.12e-05	0.000179	CcSEcCtD
Leflunomide—Hypotension—Doxorubicin—lung cancer	2.1e-05	0.000177	CcSEcCtD
Leflunomide—Urticaria—Methotrexate—lung cancer	2.06e-05	0.000174	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—lung cancer	2.05e-05	0.000173	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—lung cancer	2.05e-05	0.000173	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.05e-05	0.000172	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—lung cancer	2.03e-05	0.000171	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—lung cancer	2.02e-05	0.00017	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—lung cancer	2e-05	0.000169	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—lung cancer	1.98e-05	0.000167	CcSEcCtD
Leflunomide—Decreased appetite—Doxorubicin—lung cancer	1.95e-05	0.000164	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Doxorubicin—lung cancer	1.94e-05	0.000163	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—lung cancer	1.94e-05	0.000163	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—lung cancer	1.92e-05	0.000162	CcSEcCtD
Leflunomide—Pain—Doxorubicin—lung cancer	1.92e-05	0.000162	CcSEcCtD
Leflunomide—Hypersensitivity—Methotrexate—lung cancer	1.91e-05	0.000161	CcSEcCtD
Leflunomide—Asthenia—Methotrexate—lung cancer	1.86e-05	0.000157	CcSEcCtD
Leflunomide—Feeling abnormal—Doxorubicin—lung cancer	1.85e-05	0.000156	CcSEcCtD
Leflunomide—Gastrointestinal pain—Doxorubicin—lung cancer	1.84e-05	0.000155	CcSEcCtD
Leflunomide—Pruritus—Methotrexate—lung cancer	1.84e-05	0.000155	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—lung cancer	1.79e-05	0.00015	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—lung cancer	1.78e-05	0.00015	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—lung cancer	1.78e-05	0.00015	CcSEcCtD
Leflunomide—Diarrhoea—Methotrexate—lung cancer	1.78e-05	0.00015	CcSEcCtD
Leflunomide—Dizziness—Methotrexate—lung cancer	1.72e-05	0.000145	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—lung cancer	1.66e-05	0.000139	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—lung cancer	1.65e-05	0.000139	CcSEcCtD
Leflunomide—Rash—Methotrexate—lung cancer	1.64e-05	0.000138	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—lung cancer	1.64e-05	0.000138	CcSEcCtD
Leflunomide—Headache—Methotrexate—lung cancer	1.63e-05	0.000137	CcSEcCtD
Leflunomide—Asthenia—Doxorubicin—lung cancer	1.61e-05	0.000136	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—lung cancer	1.59e-05	0.000134	CcSEcCtD
Leflunomide—Nausea—Methotrexate—lung cancer	1.54e-05	0.00013	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—lung cancer	1.54e-05	0.000129	CcSEcCtD
Leflunomide—Dizziness—Doxorubicin—lung cancer	1.49e-05	0.000125	CcSEcCtD
Leflunomide—Vomiting—Doxorubicin—lung cancer	1.43e-05	0.00012	CcSEcCtD
Leflunomide—Rash—Doxorubicin—lung cancer	1.42e-05	0.000119	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—lung cancer	1.42e-05	0.000119	CcSEcCtD
Leflunomide—Headache—Doxorubicin—lung cancer	1.41e-05	0.000119	CcSEcCtD
Leflunomide—Nausea—Doxorubicin—lung cancer	1.34e-05	0.000112	CcSEcCtD
Leflunomide—ABCG2—Metabolism—ABCC3—lung cancer	1.18e-05	0.000155	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	1.14e-05	0.00015	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKR1C1—lung cancer	1.14e-05	0.00015	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	1.12e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CASP8—lung cancer	1.12e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6R—lung cancer	1.12e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CREBBP—lung cancer	1.11e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AVP—lung cancer	1.11e-05	0.000146	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—UGT1A1—lung cancer	1.11e-05	0.000146	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—lung cancer	1.11e-05	0.000146	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	1.11e-05	0.000145	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLBD1—lung cancer	1.09e-05	0.000143	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1R—lung cancer	1.07e-05	0.000141	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	1.07e-05	0.000141	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNG11—lung cancer	1.07e-05	0.000141	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAP2K1—lung cancer	1.06e-05	0.00014	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CD—lung cancer	1.06e-05	0.000139	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HES1—lung cancer	1.05e-05	0.000138	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ATP5H—lung cancer	1.04e-05	0.000137	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—POMC—lung cancer	1.04e-05	0.000137	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—lung cancer	1.02e-05	0.000134	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALDOA—lung cancer	1.02e-05	0.000134	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—APOA1—lung cancer	1.01e-05	0.000133	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HSD17B10—lung cancer	9.93e-06	0.000131	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NCOA3—lung cancer	9.87e-06	0.00013	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB3—lung cancer	9.62e-06	0.000127	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ADCY1—lung cancer	9.6e-06	0.000126	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	9.56e-06	0.000126	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MDM2—lung cancer	9.46e-06	0.000125	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RAF1—lung cancer	9.43e-06	0.000124	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ENO2—lung cancer	9.41e-06	0.000124	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HPGDS—lung cancer	9.41e-06	0.000124	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPP2R1B—lung cancer	9.35e-06	0.000123	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—lung cancer	9.33e-06	0.000123	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLBD1—lung cancer	9.27e-06	0.000122	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CKB—lung cancer	9.23e-06	0.000121	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—lung cancer	9.22e-06	0.000121	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CB—lung cancer	9.2e-06	0.000121	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MTOR—lung cancer	9.2e-06	0.000121	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD4—lung cancer	9.19e-06	0.000121	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTT1—lung cancer	9.13e-06	0.00012	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	9.12e-06	0.00012	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP2A6—lung cancer	9.02e-06	0.000119	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GCLC—lung cancer	9.02e-06	0.000119	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGFR1—lung cancer	8.95e-06	0.000118	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIF1A—lung cancer	8.81e-06	0.000116	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CNDP2—lung cancer	8.68e-06	0.000114	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM2—lung cancer	8.68e-06	0.000114	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ENO1—lung cancer	8.55e-06	0.000113	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—CREBBP—lung cancer	8.55e-06	0.000113	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APOA1—lung cancer	8.51e-06	0.000112	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HSD17B10—lung cancer	8.48e-06	0.000112	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—lung cancer	8.45e-06	0.000111	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTMR3—lung cancer	8.44e-06	0.000111	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KDR—lung cancer	8.43e-06	0.000111	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PGAM1—lung cancer	8.22e-06	0.000108	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—JUN—lung cancer	8.22e-06	0.000108	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—lung cancer	8e-06	0.000105	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1A—lung cancer	7.97e-06	0.000105	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—lung cancer	7.95e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CKB—lung cancer	7.89e-06	0.000104	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP2A7—lung cancer	7.85e-06	0.000103	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CG—lung cancer	7.77e-06	0.000102	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APC—lung cancer	7.77e-06	0.000102	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KIT—lung cancer	7.77e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SDC4—lung cancer	7.68e-06	0.000101	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGF—lung cancer	7.68e-06	0.000101	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP2E1—lung cancer	7.67e-06	0.000101	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NQO1—lung cancer	7.59e-06	9.99e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EP300—lung cancer	7.58e-06	9.98e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CNDP2—lung cancer	7.41e-06	9.76e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM2—lung cancer	7.41e-06	9.76e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—POMC—lung cancer	7.39e-06	9.73e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—SRC—lung cancer	7.38e-06	9.71e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BRAF—lung cancer	7.3e-06	9.61e-05	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—RAF1—lung cancer	7.23e-06	9.52e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTMR3—lung cancer	7.21e-06	9.49e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6R—lung cancer	7.21e-06	9.49e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CREBBP—lung cancer	7.2e-06	9.48e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—lung cancer	7.11e-06	9.36e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—lung cancer	7.1e-06	9.34e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PGAM1—lung cancer	7.03e-06	9.25e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RRM1—lung cancer	6.99e-06	9.21e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTA3—lung cancer	6.99e-06	9.21e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAP2K1—lung cancer	6.87e-06	9.05e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—STK11—lung cancer	6.84e-06	9e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CD—lung cancer	6.83e-06	8.99e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK3—lung cancer	6.8e-06	8.95e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP2A7—lung cancer	6.7e-06	8.83e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—B4GALT5—lung cancer	6.58e-06	8.66e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SDC4—lung cancer	6.56e-06	8.64e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—lung cancer	6.46e-06	8.51e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTA4—lung cancer	6.4e-06	8.42e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTP1—lung cancer	6.33e-06	8.33e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	6.25e-06	8.23e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTA2—lung cancer	6.23e-06	8.21e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CAT—lung cancer	6.16e-06	8.11e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MDM2—lung cancer	6.12e-06	8.05e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—lung cancer	6.11e-06	8.04e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RAF1—lung cancer	6.09e-06	8.02e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—lung cancer	6.03e-06	7.94e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTA1—lung cancer	6.01e-06	7.92e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCB1—lung cancer	5.99e-06	7.89e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RRM1—lung cancer	5.98e-06	7.87e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTA3—lung cancer	5.98e-06	7.87e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MTOR—lung cancer	5.95e-06	7.83e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CB—lung cancer	5.95e-06	7.83e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCC3—lung cancer	5.95e-06	7.83e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TYMS—lung cancer	5.88e-06	7.74e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTM1—lung cancer	5.81e-06	7.65e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKR1C1—lung cancer	5.76e-06	7.58e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—lung cancer	5.72e-06	7.53e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—B4GALT5—lung cancer	5.62e-06	7.4e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—lung cancer	5.61e-06	7.39e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—UGT1A1—lung cancer	5.59e-06	7.36e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1A1—lung cancer	5.51e-06	7.26e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—lung cancer	5.47e-06	7.21e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ERCC2—lung cancer	5.47e-06	7.2e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTA4—lung cancer	5.47e-06	7.2e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—lung cancer	5.46e-06	7.19e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNG11—lung cancer	5.39e-06	7.1e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—lung cancer	5.36e-06	7.06e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	5.34e-06	7.03e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—lung cancer	5.33e-06	7.01e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTA2—lung cancer	5.33e-06	7.01e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JUN—lung cancer	5.32e-06	7e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—lung cancer	5.19e-06	6.83e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—lung cancer	5.17e-06	6.81e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1A—lung cancer	5.15e-06	6.78e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—lung cancer	5.14e-06	6.77e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTA1—lung cancer	5.14e-06	6.77e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALDOA—lung cancer	5.13e-06	6.76e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCC3—lung cancer	5.08e-06	6.69e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NCOA3—lung cancer	4.98e-06	6.56e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—lung cancer	4.97e-06	6.54e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKR1C1—lung cancer	4.92e-06	6.48e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EP300—lung cancer	4.9e-06	6.46e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	4.9e-06	6.45e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ADCY1—lung cancer	4.85e-06	6.38e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCG2—lung cancer	4.85e-06	6.38e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—UGT1A1—lung cancer	4.78e-06	6.29e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SRC—lung cancer	4.77e-06	6.28e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ENO2—lung cancer	4.75e-06	6.26e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HPGDS—lung cancer	4.75e-06	6.26e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOA1—lung cancer	4.73e-06	6.23e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPP2R1B—lung cancer	4.72e-06	6.22e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	4.66e-06	6.14e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—lung cancer	4.64e-06	6.11e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTT1—lung cancer	4.61e-06	6.07e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNG11—lung cancer	4.61e-06	6.06e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—lung cancer	4.6e-06	6.05e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—lung cancer	4.59e-06	6.04e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	4.58e-06	6.03e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—lung cancer	4.58e-06	6.03e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GCLC—lung cancer	4.56e-06	6e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP2A6—lung cancer	4.56e-06	6e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	4.54e-06	5.98e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK3—lung cancer	4.39e-06	5.78e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALDOA—lung cancer	4.39e-06	5.77e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ENO1—lung cancer	4.32e-06	5.69e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CG—lung cancer	4.32e-06	5.68e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	4.3e-06	5.67e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—lung cancer	4.27e-06	5.63e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NCOA3—lung cancer	4.26e-06	5.61e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	4.25e-06	5.59e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	4.18e-06	5.51e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—lung cancer	4.18e-06	5.5e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCG2—lung cancer	4.14e-06	5.45e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ADCY1—lung cancer	4.14e-06	5.45e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—POMC—lung cancer	4.11e-06	5.41e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENO2—lung cancer	4.06e-06	5.35e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HPGDS—lung cancer	4.06e-06	5.35e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPP2R1B—lung cancer	4.04e-06	5.31e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CREBBP—lung cancer	4e-06	5.27e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.98e-06	5.24e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—lung cancer	3.95e-06	5.2e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTT1—lung cancer	3.94e-06	5.19e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GCLC—lung cancer	3.89e-06	5.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP2A6—lung cancer	3.89e-06	5.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.88e-06	5.11e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP2E1—lung cancer	3.88e-06	5.1e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NQO1—lung cancer	3.83e-06	5.04e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CD—lung cancer	3.8e-06	5e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.75e-06	4.94e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—lung cancer	3.75e-06	4.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.72e-06	4.89e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENO1—lung cancer	3.69e-06	4.86e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.68e-06	4.84e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.63e-06	4.78e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—lung cancer	3.63e-06	4.78e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—lung cancer	3.51e-06	4.62e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—STK11—lung cancer	3.45e-06	4.55e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—lung cancer	3.36e-06	4.42e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP2E1—lung cancer	3.31e-06	4.36e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CB—lung cancer	3.31e-06	4.36e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—lung cancer	3.28e-06	4.32e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NQO1—lung cancer	3.27e-06	4.31e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.24e-06	4.27e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—lung cancer	3.21e-06	4.23e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.21e-06	4.22e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTP1—lung cancer	3.2e-06	4.21e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.18e-06	4.18e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CAT—lung cancer	3.11e-06	4.09e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.09e-06	4.07e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCB1—lung cancer	3.03e-06	3.98e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMS—lung cancer	2.97e-06	3.91e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—lung cancer	2.96e-06	3.9e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—STK11—lung cancer	2.95e-06	3.89e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM1—lung cancer	2.94e-06	3.87e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—lung cancer	2.86e-06	3.76e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1A1—lung cancer	2.78e-06	3.67e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.77e-06	3.65e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ERCC2—lung cancer	2.76e-06	3.64e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTP1—lung cancer	2.73e-06	3.6e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—EP300—lung cancer	2.73e-06	3.59e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CAT—lung cancer	2.66e-06	3.5e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.64e-06	3.48e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCB1—lung cancer	2.59e-06	3.4e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMS—lung cancer	2.54e-06	3.34e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM1—lung cancer	2.51e-06	3.3e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOA1—lung cancer	2.39e-06	3.14e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP1A1—lung cancer	2.38e-06	3.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ERCC2—lung cancer	2.36e-06	3.11e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.29e-06	3.01e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CG—lung cancer	2.18e-06	2.87e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—POMC—lung cancer	2.08e-06	2.73e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOA1—lung cancer	2.04e-06	2.69e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CREBBP—lung cancer	2.02e-06	2.66e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—lung cancer	2.02e-06	2.66e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.95e-06	2.57e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CD—lung cancer	1.92e-06	2.52e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—lung cancer	1.89e-06	2.49e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CG—lung cancer	1.86e-06	2.45e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—POMC—lung cancer	1.77e-06	2.34e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CREBBP—lung cancer	1.73e-06	2.27e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CB—lung cancer	1.67e-06	2.2e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—lung cancer	1.66e-06	2.18e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—lung cancer	1.65e-06	2.17e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CD—lung cancer	1.64e-06	2.16e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—lung cancer	1.62e-06	2.13e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—lung cancer	1.44e-06	1.9e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CB—lung cancer	1.43e-06	1.88e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—lung cancer	1.41e-06	1.86e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—EP300—lung cancer	1.38e-06	1.81e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—lung cancer	1.23e-06	1.62e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—EP300—lung cancer	1.18e-06	1.55e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—lung cancer	1.02e-06	1.34e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—lung cancer	8.7e-07	1.15e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—lung cancer	8.32e-07	1.1e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—lung cancer	7.11e-07	9.36e-06	CbGpPWpGaD
